Try our beta test site
5 studies found for:    c-myc | Open Studies | diffuse large b-cell lymphoma OR DLBCL
Show Display Options
Rank Status Study
1 Recruiting Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
Conditions: Burkitt Lymphoma;   Diffuse Large B-cell Lymphoma, c-MYC Positive;   Plasmablastic Lymphoma
Interventions: Drug: EPOCH-R;   Drug: EPOCH-RR
2 Recruiting DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma
Condition: Diffuse Large B-Cell Lymphoma
Intervention: Drug: Metformin
3 Recruiting A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas
Conditions: Diffuse Large B-cell Lymphoma;   Follicular Lymphoma;   Burkitt Lymphoma
Intervention: Drug: Alisertib
4 Not yet recruiting Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Conditions: Adult Burkitt Lymphoma;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   Diffuse Large B-Cell Lymphoma;   MYC Gene Mutation;   Plasmablastic Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Prednisone;   Biological: Rituximab;   Drug: Therapeutic Hydrocortisone;   Drug: Vincristine Sulfate
5 Recruiting An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Condition: Advanced Cancer
Intervention: Drug: INCB054329 Monotherapy

Study has passed its completion date and status has not been verified in more than two years.